IMMUNOHISTOCHEMICAL BIOMARKERS IN EC 123 5 syndrome screening panel and so refining the choice of adjuvant treatment42. The recently published ENDORISK model demonstrates that preoperative identification for patients at risk for LNM can be significantly improved by incorporating clinical and IHC biomarkers into a Bayesian network9. Although we fully endorse the integration of both clinical and IHC biomarkers, in clinical practice we often have to deal with incomplete data. This current study showed that the IHC biomarkers could serve as indicator for LN directed surgery and either IHC biomarkers or molecular profiling or a combination, could be used as refinement for selective adjuvant treatment by being incorporated in the ESMO-ESGO-ESTRO risk classification and being used next to LN status. These results should be further validated in an prospective study with an independent cohort. CONCLUSION Concluding, preoperative IHC biomarkers are important prognostic markers within the ESMO-ESGO-ESTRO risk classification groups and in addition to LN status. For daily clinical practice, integrating IHC expression of p53/L1CAM/ER/PR into the ESMO-ESGOESTRO risk classification groups may be valuable in guiding surgical staging, and identifying patients who would benefit from specific adjuvant treatment.
RkJQdWJsaXNoZXIy MTk4NDMw